Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis

New England Journal of Medicine

Volumn 325, Issue 7, 1991, Pages 467-472

  Sharief, Mohammad K ^a   Hentges, Romain ^b  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b FREE UNIVERSITY OF BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD LEVEL; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

EID: 0025773147     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199108153250704     Document Type: Article

References (43)

1. Ebers G.C. Multiple sclerosis and other demyelinating diseases. In: Asbury AK, McKhann GM, McDonald WI, eds. Diseases of the nervous system. Philadelphia: Ardmore Medical Books, 1986: 1268-81.
2. Tourtellotte W.W., Baumhefner R., Syndulko K., et al. The long march of the cerebrospinal fluid profile indicative of clinical definite multiple sclerosis; and still marching. J Neuroimmunol 1988; 20:217-227
3. Waksman B.H., Reynolds W.E. Multiple sclerosis as a disease of immunoregulation. Proc Soc Exp Biol Med 1984; 175:282-294
4. Hauser S.L., Bhan A.K., Gilles F., Kemp M., Kerr C., Weiner H.L. Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Ann Neurol 1986; 19:578-587
5. Mustafa M.M., Ramilo O., Saez-Llorens X., Mertsola J., McCracken G.H. Jr. Role of tumor necrosis factor-α (cachectin) in experimental and clinical bacterial meningitis. Pediatr Infect Dis J 1989; 8:907-908
6. Mustafa M.M., Lebel M.H., Ramilo O., et al. Correlation of interleukin-1 beta and cachectin concentrations in cerebrospinal fluid and outcome from bacterial meningitis. J Pediatr 1989; 115:208-213
7. Mintz M., Rapaport R., Oleske J.M., et al. Elevated serum levels of tumor necrosis factor are associated with progressive encephalopathy in children with acquired immunodeficiency syndrome. Am J Dis Child 1989; 143:771-774
8. Selmaj K.W., Raine C.S. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988; 23:339-346
9. Poser C.M., Paty D.W., Scheinberg L., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13:227-231
10. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33:1444-1452
11. Jersild C., Fog T., Hansen G., Thomsen M., Svejgaard A., Dupont B. Histocompatibility determinants in multiple sclerosis, with special reference to clinical course. Lancet 1973; 2:1221-1225
12. Poser S., Raun N.E., Poser W. Age at onset, initial symptomatology and course of multiple sclerosis. Acta Neurol Scand 1982; 66:355-362
13. Noseworthy J.H., Vandervoot M.K., Wong C.J., Ebers G.C. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. Neurology 1990; 40:971-975
14. Michie H.R., Manogue K.R., Spriggs D.R., et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988; 318:1481-1486
15. Walker R., Keir G., Johnson M.H., Thompson E.J. A rapid method for detecting oligoclonal IgG in unconcentrated CSF, by agarose isoelectric focusing, transfer to cellulose nitrate and immunoperoxidase staining. J Neuroimmunol 1983; 4:141-148
16. Tourtellotte W.W., Ma B.I. Multiple sclerosis: the blood–brain barrier and the measurement of de novo central nervous system IgG synthesis. Neurology 1978; 28:76-83.
17. Luxton R., Patel P., Keir G., Thompson E.J. A micro-method for measuring total protein in cerebrospinal fluid by using benzethonium chloride in microtiter plate wells. Clin Chem 1989; 35:1731-1734
18. Campbell M.J., Gardner M.J. Calculating confidence intervals for some nonparametric analyses. BMJ 1988; 296:1454-1456
19. McCullagh P., Nelder J.A. Generalized linear models. London: Chapman & Hall, 1983: 99-106.
20. Brosnan C.F., Selmaj K., Raine C.S. Hypothesis: a role for tumor necrosis factor in immune-mediated demyelination and its relevance to multiple sclerosis. J Neuroimmunol 1988; 18:87-94.
21. Beck J., Rondot P., Catinot L., Falcoff E., Kirchner H., Wietzerbin J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand 1988; 78:318-323
22. The Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. Ann Neurol 1990; 27:591-605.
23. The Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991; 337:441-446
24. Hauser S.L., Dawson D.M., Lehrich J.R., et al. Intensive immunosuppression in progressive multiple sclerosis: a randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983; 308:173-180
25. Khatri B.O., McQuillen M.P., Harrington G.J., Schmoll D., Hoffmann R.G. Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs. Neurology 1985; 35:312-319
26. Goodkin D.E., Plencner S., Palmer-Saxerud J., Teetzen M., Hertsgaard D. Cyclophosphamide in chronic progressive multiple sclerosis: maintenance vs. nonmaintenance therapy. Arch Neurol 1987; 44:823-827
27. Trotter J.L., Clifford D.B., Mclnnis J.E., et al. Correlation of immunological studies and disease progression in chronic progressive multiple sclerosis. Ann Neurol 1989; 25:172-178
28. Gallo P., Piccinno M., Tavolato B., Sidén Å. A longitudinal study on IL-2, SIL-2R, IL-4 and IFN-γ in multiple sclerosis CSF and serum. J Neurol Sci 1991; 101:227-232
29. Slungaard A., Vercellotti G.M., Walker G., Nelson R.D., Jacob H.S. Tumor necrosis factor-α/cachectin stimulates eosinophil oxidant production and toxicity towards human endothelium. J Exp Med 1990; 171:2025-2041
30. Tracey K.J., Wei H., Manogue K.R., et al. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med 1987; 167:1211-1227
31. James P.B. Multiple sclerosis or blood–brain barrier disease. Lancet 1989; 1:46.
32. Kermode A.G., Thompson A.J., Tofts P., et al. Breakdown of the blood–brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis: pathogenetic and clinical implications. Brain 1990; 113:1477-1489
33. Gay D., Esiri M.M. Blood–brain barrier damage in acute multiple sclerosis plaques: an immunocytological study. Brain 1991; 114:557-572
34. Adams C.W., Poston R.N., Buk S.J. Pathology, histochemistry and immunocytochemistry of lesions in acute multiple sclerosis. J Neurol Sci 1989; 92:291-306.
35. Chung I.Y., Benveniste E.N. Tumor necrosis factor-α production by astrocytes: induction by lipopolysaccharide, IFN-γ, and IL-lβ. J Immunol 1990; 144:2999-3007.
36. Robbins D.S., Shirazi Y., Drysdale B.E., Lieberman A., Shin H.S., Shin M.L. Production of cytotoxic factor for oligodendrocytes by stimulated astrocytes. J Immunol 1987; 139:2593-2597
37. Hofman F.M., Hinton D.R., Johnson K., Merrill J.E. Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 1990; 170:607-612
38. Franciotta D.M., Grimaldi L.M., Martino G.V., et al. Tumor necrosis factor in serum and cerebrospinal fluid of patients with multiple sclerosis. Ann Neurol 1989; 26:787-789
39. McLaughlin P.J., Elmwood N.J., Ramadi L.T., Pica M.R., McKenzie I.F. Improvement in sensitivity of enzyme-linked immunosorbent assay of tumor necrosis factor. Immunol Cell Biol 1990; 68:51-55
40. Maimone D., Gregory S., Arnason B.G., Reder A.T. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol 1991; 32:67-74.
41. Bjorvatn B., Bjertnaes L., Fadnes H.O., et al. Meningococcal septicaemia treated with combined plasmapheresis and leucapheresis or with blood exchange. BMJ 1984; 288:439-441
42. Tracey K.J., Fong Y., Hesse D.G., et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330:662-664
43. Robertson B., Dostal K., Daynes R.A. Neuropeptide regulation of inflammatory and immunologic responses: the capacity of α-melanocyte-stimulating hormone to inhibit tumor necrosis factor and IL-1-inducible biologic responses. J Immunol 1988; 140:4300-4307